Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Pemetrexed After Progression on Platinum-Based Therapy in Advanced Thymic Epithelial Tumors
KCT0004180Phase 2Not yet recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed in thymic malignancies (TET), sponsored by Samyang Biopharmaceuticals Corporation. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
pemetrexed
03
Conditions
thymic malignancies (TET)
Beyond the preview
Go deeper on KCT0004180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004180.